Agency Forms Undergoing Paperwork Reduction Act Review, 80106-80107 [2020-27326]
Download as PDF
<![CDATA[
80106
Federal Register / Vol. 85, No. 239 / Friday, December 11, 2020 / Notices
successful implementation and
evaluation of surveillance and
prevention activities. The OD2A TA
Center is designed to enhance the
efficiency, coordination, and
effectiveness of TA efforts by
streamlining and centralizing the
provision of overdose surveillance and
prevention TA. TA to OD2A recipients
is divided into four different levels with
multiple modes of TA delivery and
involves a wide range of TA providers
including CDC staff, internal and
external subject matter experts (SMEs)
and program partners as well as ICF
staff.
obtained through this evaluation will
allow TA providers to assess OD2A
recipients’ experience and utility of
knowledge and resources gained
through individual TA support, peer-topeer sessions, and other group trainings.
Ultimately, the evaluation data will
inform subsequent rounds of TA and
allow TA providers to make necessary
adjustments to the overall TA strategy
for continuous quality improvement.
This will ensure recipients have the
support necessary to implement
strategies that will improve opioid
surveillance and prevention policies
and practices within their communities.
The evaluation consists of two webbased surveys designed to collect
process and outcome measures about
TA access, utilization, and outcomes
across all 66 OD2A recipient programs.
The Technical Assistance Feedback
Form will be administered to collect
immediate feedback following
individual TA encounters and group
events such as webinars and in-person
trainings. The Annual OD2A TA Survey
will be distributed twice (mid-point and
final) to assess satisfaction with overall
TA provided and the extent to which
TA supports informed implementation
of OD2A strategies. The information
ESTIMATED ANNUALIZED BURDEN HOURS
Average
burden per
response
(in hours)
Total burden
(in hours)
Form name
OD2A Recipients ..............................
Annual OD2A TA Survey ..................
TA Feedback Form ..........................
...........................................................
671
440
2
1
5/60
15/60
112
110
Total ...........................................
...........................................................
........................
........................
........................
222
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2020–27325 Filed 12–10–20; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–21–20OT]
Agency Forms Undergoing Paperwork
Reduction Act Review
jbell on DSKJLSW7X2PROD with NOTICES
Number of
responses per
respondent
Number of
respondents
Type of respondents
In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled ‘‘Mycoplasma
genitalium Treatment Failure Registry’’
to the Office of Management and Budget
(OMB) for review and approval. CDC
previously published a ‘‘Proposed Data
Collection Submitted for Public
Comment and Recommendations’’
notice on June 5, 2020 to obtain
comments from the public and affected
agencies. CDC did not receive comments
related to the previous notice. This
notice serves to allow an additional 30
days for public and affected agency
comments.
CDC will accept all comments for this
proposed information collection project.
The Office of Management and Budget
VerDate Sep<11>2014
00:32 Dec 11, 2020
Jkt 253001
is particularly interested in comments
that:
(a) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(b) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and
(e) Assess information collection
costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570.
Comments and recommendations for the
proposed information collection should
be sent within 30 days of publication of
this notice to www.reginfo.gov/public/
do/PRAMain Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function. Direct written
PO 00000
Frm 00117
Fmt 4703
Sfmt 4703
comments and/or suggestions regarding
the items contained in this notice to the
Attention: CDC Desk Officer, Office of
Management and Budget, 725 17th
Street NW, Washington, DC 20503 or by
fax to (202) 395–5806. Provide written
comments within 30 days of notice
publication.
Proposed Project
Mycoplasma genitalium Treatment
Failure Registry—New—National Center
for HIV/AIDS, Viral Hepatitis, STD, and
TB Prevention (NCHHSTP), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
The Centers for Disease Control and
Prevention (CDC), Division of STD
Prevention requests a three-year
approval of an information collection
request for the Mycoplasma genitalium
Treatment Failure Registry, which will
entail use of a standardized Case Report
Form.
The primary goal of this activity is to
establish a registry to monitor cases of
Mycoplasma genitalium (M. genitalium)
treatment failure in the United States.
The project objectives are as follows: (1)
Using existing clinical data, describe
demographic and behavioral factors
among patients with documented
Mycoplasma genitalium who fail
current CDC-recommended treatment,
(2) Using existing clinical data, describe
antibiotic regimens utilized among
patients with Mycoplasma genitalium
treatment failure, including
documentation of clinical and
E:\FR\FM\11DEN1.SGM
11DEN1
80107
Federal Register / Vol. 85, No. 239 / Friday, December 11, 2020 / Notices
microbiologic cure, (3) Using existing
laboratory specimens, monitor genetic
mutations associated with macrolide or
fluroquinolone antibiotic resistance.
Data captured on the standardized
Case Report Form will be analyzed to
determine outcomes from usage of
second-line antibiotic therapy for
M.gentialium. These data may inform
future CDC STD Treatment Guidelines.
There are an estimated 100 respondents
(anticipated to report once per year)
who will be clinicians in private and
public health care settings. The data
collection is necessary as there are no
current national recommendations for
patients who fail current CDCrecommended therapy for M.
genitalium. Each case report form is
anticipated to take up to 60 minutes to
complete. This data collection provides
CDC with information to determine
which second-line treatments are most
clinically effective, as well as
determining antibiotic resistance
patterns of M. genitalium throughout the
US. There are no costs to respondents
other than their time. The estimated
annualized burden hours for this data
collection are 100 hours.
ESTIMATED ANNUALIZED BURDEN HOURS
Type of respondent
Physician or Nurse Practitioner.
M. genitalium Treatment Failure Registry Case Report Form
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2020–27326 Filed 12–10–20; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Closed Meeting
jbell on DSKJLSW7X2PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Disease, Disability,
and Injury Prevention and Control Special
Emphasis Panel (SEP)-DP21–002,
Epidemiologic Cohort Study of Interstitial
Cystitis.
Date: March 30, 2021.
Time: 10:00 a.m.–6:00 p.m., EST.
Place: Teleconference.
Agenda: To review and evaluate grant
applications.
VerDate Sep<11>2014
23:25 Dec 10, 2020
No. of Respondents
Form name
Jkt 253001
For Further Information Contact: Jaya
Raman Ph.D., Scientific Review Officer, CDC,
4770 Buford Highway, Mailstop F80, Atlanta,
Georgia 30341, Telephone: (770) 488–6511,
JRaman@cdc.gov.
The Director, Strategic Business Initiatives
Unit, Office of the Chief Operating Officer,
Centers for Disease Control and Prevention,
has been delegated the authority to sign
Federal Register notices pertaining to
announcements of meetings and other
committee management activities, for both
the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives
Unit,Office of the Chief Operating
Officer,Centers for Disease Control and
Prevention.
[FR Doc. 2020–27229 Filed 12–10–20; 8:45 am]
100
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Centers for Disease Control and
Prevention (CDC)/Health Resources
and Services Administration (HRSA)
Advisory Committee on HIV, Viral
Hepatitis and STD Prevention and
Treatment (CHACHSPT); Notice of
Charter Renewal
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of charter renewal.
AGENCY:
FOR FURTHER INFORMATION CONTACT:
Jonathan Mermin, MD, MPH,
Designated Federal Officer, Centers for
Disease Control and Prevention (CDC)/
Health Resources and Services
Administration (HRSA) Advisory
Committee on HIV, Viral Hepatitis and
STD Prevention and Treatment
(CHACHSPT), CDC, HHS, 1600 Clifton
Road NE, Mailstop US8–6, Atlanta,
Georgia 30329–4027; Telephone (404)
639–8000, JMermin@cdc.gov.
The
Director, Strategic Business Initiatives
Unit, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention, has been delegated the
authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2020–27227 Filed 12–10–20; 8:45 am]
BILLING CODE 4163–18–P
This gives notice under the
Federal Advisory Committee Act of
October 6, 1972, that the Centers for
Disease Control and Prevention (CDC)/
Health Resources and Services
Administration (HRSA) Advisory
Committee on HIV, Viral Hepatitis and
Fmt 4703
1
STD Prevention and Treatment
(CHACHSPT), Centers for Disease
Control and Prevention, Department of
Health and Human Services, has been
renewed for a 2-year period through
November 25, 2022.
SUMMARY:
Frm 00118
Average burden per response
(in hours)
SUPPLEMENTARY INFORMATION:
BILLING CODE 4163–18–P
PO 00000
No. responses
per respondent
Sfmt 9990
E:\FR\FM\11DEN1.SGM
11DEN1
1
]]>Agencies
[Federal Register Volume 85, Number 239 (Friday, December 11, 2020)]
[Notices]
[Pages 80106-80107]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-27326]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-21-20OT]
Agency Forms Undergoing Paperwork Reduction Act Review
In accordance with the Paperwork Reduction Act of 1995, the Centers
for Disease Control and Prevention (CDC) has submitted the information
collection request titled ``Mycoplasma genitalium Treatment Failure
Registry'' to the Office of Management and Budget (OMB) for review and
approval. CDC previously published a ``Proposed Data Collection
Submitted for Public Comment and Recommendations'' notice on June 5,
2020 to obtain comments from the public and affected agencies. CDC did
not receive comments related to the previous notice. This notice serves
to allow an additional 30 days for public and affected agency comments.
CDC will accept all comments for this proposed information
collection project. The Office of Management and Budget is particularly
interested in comments that:
(a) Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
(b) Evaluate the accuracy of the agencies estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and clarity of the information to
be collected;
(d) Minimize the burden of the collection of information on those
who are to respond, including, through the use of appropriate
automated, electronic, mechanical, or other technological collection
techniques or other forms of information technology, e.g., permitting
electronic submission of responses; and
(e) Assess information collection costs.
To request additional information on the proposed project or to
obtain a copy of the information collection plan and instruments, call
(404) 639-7570. Comments and recommendations for the proposed
information collection should be sent within 30 days of publication of
this notice to www.reginfo.gov/public/do/PRAMain Find this particular
information collection by selecting ``Currently under 30-day Review--
Open for Public Comments'' or by using the search function. Direct
written comments and/or suggestions regarding the items contained in
this notice to the Attention: CDC Desk Officer, Office of Management
and Budget, 725 17th Street NW, Washington, DC 20503 or by fax to (202)
395-5806. Provide written comments within 30 days of notice
publication.
Proposed Project
Mycoplasma genitalium Treatment Failure Registry--New--National
Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP),
Centers for Disease Control and Prevention (CDC).
Background and Brief Description
The Centers for Disease Control and Prevention (CDC), Division of
STD Prevention requests a three-year approval of an information
collection request for the Mycoplasma genitalium Treatment Failure
Registry, which will entail use of a standardized Case Report Form.
The primary goal of this activity is to establish a registry to
monitor cases of Mycoplasma genitalium (M. genitalium) treatment
failure in the United States. The project objectives are as follows:
(1) Using existing clinical data, describe demographic and behavioral
factors among patients with documented Mycoplasma genitalium who fail
current CDC-recommended treatment, (2) Using existing clinical data,
describe antibiotic regimens utilized among patients with Mycoplasma
genitalium treatment failure, including documentation of clinical and
[[Page 80107]]
microbiologic cure, (3) Using existing laboratory specimens, monitor
genetic mutations associated with macrolide or fluroquinolone
antibiotic resistance.
Data captured on the standardized Case Report Form will be analyzed
to determine outcomes from usage of second-line antibiotic therapy for
M.gentialium. These data may inform future CDC STD Treatment
Guidelines. There are an estimated 100 respondents (anticipated to
report once per year) who will be clinicians in private and public
health care settings. The data collection is necessary as there are no
current national recommendations for patients who fail current CDC-
recommended therapy for M. genitalium. Each case report form is
anticipated to take up to 60 minutes to complete. This data collection
provides CDC with information to determine which second-line treatments
are most clinically effective, as well as determining antibiotic
resistance patterns of M. genitalium throughout the US. There are no
costs to respondents other than their time. The estimated annualized
burden hours for this data collection are 100 hours.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average burden
Type of respondent Form name No. of No. responses per response
Respondents per respondent (in hours)
----------------------------------------------------------------------------------------------------------------
Physician or Nurse Practitioner....... M. genitalium Treatment 100 1 1
Failure Registry Case
Report Form.
----------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Scientific
Integrity, Office of Science, Centers for Disease Control and
Prevention.
[FR Doc. 2020-27326 Filed 12-10-20; 8:45 am]
BILLING CODE 4163-18-P
